Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN On-line: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2013007934
pages 449-461

Iron in Multiple Myeloma

Kristina VanderWall
Division of Hematology-Oncology, Department of Medicine, UCLA David Geffen School of Medicine
Tracy R. Daniels-Wells
Division of Surgical Oncology, Department of Surgery, UCLA David Geffen School of Medicine
Manuel Penichet
Division of Surgical Oncology, Department of Surgery, UCLA David Geffen School of Medicine; The Jonsson Comprehensive Cancer Center, The Molecular Biology Institute, Department of Microbiology, Immunology, and Molecular Genetics, UCLA
Alan Llichtenstein
Division of Hematology-Oncology, Department of Medicine, UCLA David Geffen School of Medicine; The Jonsson Comprehensive Cancer Center, UCLA; The Greater Los Angeles VA Medical Center, Los Angeles, California

RESUMO

Multiple myeloma is a non-curable B-cell malignancy in which iron metabolism plays an important role. Patients with this disorder almost universally suffer from clinically significant anemia, which is often symptomatic, and which is due to impaired iron utilization. Recent studies have indicated that the proximal cause of dysregulated iron metabolism and anemia in these patients is cytokine-induced upregulation of hepcidin expression. Malignant myeloma cells are dependent on an increased influx of iron, and therapeutic efforts are being made to target this requirement. The studies detailing the characteristics and biochemical abnormalities in iron metabolism causing anemia and the initial attempts to target iron therapeutically are described in this review.


Articles with similar content:

Signaling Pathways in Pancreatic Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 2
Meir Preis , Murray Korc
Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 2
Lian-wen Zheng, Dan-dan Li, Lu-lu Fu, Feng-ge Wang, Ying Xu, Xue-ying Zhang, Xu Zhou, Ling-yun Li, Shu-xiong Chen, Chun-jin Li
Inhibition of STAT3 Activation by RKIP in Colon Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 1
Devasis Chatterjee, Erika L. Moen, Y. Eugene Chin
Hemiepiphysiodeses for Guided Growth in Children
Journal of Long-Term Effects of Medical Implants, Vol.24, 2014, issue 2-3
Andreas Karameris, George C. Babis, Ioannis Christogiannis, Kleo Papaparaskeva, George Nomikos, Dimitrios Koulalis, Andreas F. Mavrogenis, Apostolos Papalois, Dimitrios Dovris
Cancer and Cancer Stem Cells: New Molecular Perspectives
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Onur Sahin, Gokce Ceren Kuscu, Gulperi Oktem, Elif Tunc, Funda Cagirir Dindaroglu, Cevik Gurel, Ismet Hortu, Gizem Inetas, Aylin Buhur